#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	7750	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2591	716.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1605	1605	C	941	C,A,T	826,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12414	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4125	724.5	0	.	n	.	0	T695C	SNP	695	695	T	1299	1299	C	802	C,T,G	689,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12414	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4125	724.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1941	1941	A	855	A,C,G	771,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12414	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4125	724.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2575	2575	C	872	C,A,G	783,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12414	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4125	724.5	0	.	n	.	0	C2403T	SNP	2403	2403	C	3007	3007	T	963	T,C,G	619,228,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12414	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4125	724.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2649	2649	A	833	A,T,G	745,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12414	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4125	724.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3201	3201	C	869	C,T	783,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	872	folP	855	855	100.0	folP.l15.c4.ctg.1	1855	112.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1204	1206	AGC	128;127;128	A;G;C	118;117;117	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2094	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4172	122.8	1	SNP	p	S91F	1	.	.	271	273	TTC	1007	1009	TTC	155;155;155	T,G;T;C,T	132,1;133;135,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2094	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4172	122.8	1	SNP	p	D95G	1	.	.	283	285	GGC	1019	1021	GGC	157;161;161	G,T;G;C,A	137,1;144;140,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2094	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4172	122.8	1	SNP	p	G95N	0	.	.	283	285	GGC	1019	1021	GGC	157;161;161	G,T;G;C,A	137,1;144;140,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	824	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1668	120.9	1	SNP	p	G45D	0	.	.	133	135	GGC	665	667	GGC	183;183;183	G;G;C	158;160;161	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	506	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1561	78.5	0	.	n	.	0	A197.	DEL	197	197	A	868	868	A	190	A	168	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	125.0	1	SNP	p	D86N	0	.	.	256	258	GAC	860	862	GAC	126;128;133	G;A,C;C,A	101;85,2;109,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	125.0	1	SNP	p	R87W	0	.	.	259	261	CGT	863	865	CGT	135;135;138	C;G,T;T,G	117;100,1;113,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	125.0	1	SNP	p	R87I	0	.	.	259	261	CGT	863	865	CGT	135;135;138	C;G,T;T,G	117;100,1;113,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	125.0	1	SNP	p	S87R	1	.	.	259	261	CGT	863	865	CGT	135;135;138	C;G,T;T,G	117;100,1;113,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	125.0	1	SNP	p	S88P	0	.	.	262	264	TCC	866	868	TCC	139;139;138	T;C,T;C	118;113,1;123	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1780	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3254	134.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1902	1904	GGC	145;149;149	G;G;C	130;131;132	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1619	1621	GCA	214;215;215	G,A;C;A	187,1;192;193	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1622	1624	ATC	216;216;215	A;T,G,A;C	191;194,1,1;197	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1634	1636	GTG	211;210;210	G;T,A;G	193;192,2;192	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1634	1636	GTG	211;210;210	G;T,A;G	193;192,2;192	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2138	2140	ACC	127;127;124	A,C;C,A;C,G	105,1;106,1;110,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2192	2194	GCG	107;110;111	G;C;G,C	85;83;85,1	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2192	2194	GCG	107;110;111	G;C;G,C	85;83;85,1	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2315	2317	AGC	112;114;116	A,C;G,T,A;C,T	105,2;106,1,1;108,2	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2324	2326	GGC	107;107;106	G,T;G;C	99,1;97;98	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1610	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2651	145.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2342	2344	CCG	102;102;102	C,G;C;G,C	90,1;90;91,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2118	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3559	141.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1841	1843	CCG	200;200;200	C,G,T,A;C,T;G,C,A	161,5,1,2;180,1;153,5,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	952	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2377	97.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	826	826	C	91	C	74	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	594	596	GGA	168;167;168	G;G;A	155;153;158	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	V75I	NONSYN	223	225	GTT	675	677	ATT	171;171;170	A;T;T	160;159;161	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	T89S	NONSYN	265	267	ACC	717	719	AGC	176;176;178	A;G;C	167;166;165	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	V98I	NONSYN	292	294	GTC	744	746	ATC	183;183;182	A,C;T,C;C	168,1;163,1;172	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	.	MULTIPLE	358	359	AA	809	810	CG	152;152	C,T;G,C	140,1;125,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	.	MULTIPLE	361	362	GA	812	814	CAG	147;146;146	C;A;G	130;126;132	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	N122K	NONSYN	364	366	AAC	816	818	AAA	149;151;153	A,C;A,C;A	133,4;139,1;142	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	843	845	TAT	160;161;161	T,G;A,C;T	147,1;146,1;136	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	N134E	NONSYN	400	402	AAT	852	854	GAG	163;165;165	G,T;A;G,A	141,1;146;140,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	V135L	NONSYN	403	405	GTG	855	857	CTT	167;168;170	C,T;T,C;T	145,1;148,1;159	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	G140K	NONSYN	418	420	GGA	870	872	AAA	177;177;178	A,C;A;A	161,1;164;162	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	K143E	NONSYN	427	429	AAA	879	881	GAA	179;181;181	G;A;A	155;150;158	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	V151A	NONSYN	451	453	GTA	903	905	GCA	179;178;179	G;C;A	160;157;156	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	A196V	NONSYN	586	588	GCC	1038	1040	GTC	191;188;188	G,C;T,G,A;C,T	181,1;170,1,1;176,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1089	1091	TCA	209;216;220	T,G;C;A,C,G	201,1;208;208,2,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1209	1211	CAA	182;181;181	C,A;A;A	169,1;169;169	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	.	INDELS	760	762	ACA	1213	1217	ATCAA	183;181;180;180;180	A,C;T;C,A;A;A	170,1;169;167,1;168;168	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	.	INDELS	763	764	TG	1220	1222	AGT	181;181;177	A,T;G;T,C,A	167,1;169;156,4,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1227	1229	GAT	175;175;175	G,C;A,T;T	161,1;160,1;162	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1263	1265	AGC	180;179;179	A,T;G,T;C,A	161,1;164,2;161,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1335	1337	AGT	189;189;185	A;G,C;T,G,C	181;179,1;173,2,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1341	1343	GAC	179;178;178	G;A,C;C	167;166,1;164	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1344	1346	TAC	177;175;177	T;A,C;C	166;162,1;166	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	1	SNP	p	G120K	1	.	.	358	360	AAG	809	811	CGG	152;152;152	C,T;G,C;G	140,1;125,2;132	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	1	SNP	p	A121D	1	.	.	361	363	GAC	812	815	CGC	147;146;149	C;G;C	130;132;136	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1092	porB1b	1041	1041	96.28	porB1b.l6.c30.ctg.1	2031	130.6	1	SNP	p	D121N	0	.	.	361	363	GAC	812	815	CGC	147;146;149	C;G;C	130;132;136	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	4540	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5304	208.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	620	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1618	95.0	1	SNP	p	V57M	1	.	.	169	171	ATG	848	850	ATG	222;221;221	A;T;G	201;205;205	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
